

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL
RECEIVED
CENTRAL FAX CENTER
SEP 12 2003

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner E. Slobodyansky, fax number (703) 308-4242.

Respectfully submitted,

Date: September 11, 2003


Elias J. Lambiris
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

SEP 12 2003

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed March 11, 2003.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from June 11, 2003 to September 11, 2003. The required fee for the extension is estimated to be \$930.

The fee for claims has been calculated as shown below:

Total: $29 - 26 = 3 \times 18 = \54


Independent: $1 - 3 = 0 \times 84 = \$0$

Total additional fee for claims required is \$54

Please charge the required extension and claims fees, estimated to be \$984, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 11, 2003


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed March 11, 2003, please amend the above-identified application as follows: